Overview

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Status:
NOT_YET_RECRUITING

Trial end date:
2026-10-30

Target enrollment:

Participant gender:

Summary

In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare outcome of adjuvant cisplatin and gemcitabine versus capecitabine

Phase:

PHASE2

Details

Lead Sponsor:

Assiut University

Treatments:

Capecitabine
Cisplatin
Gemcitabine